Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine vs Esmolol in Septic Shock
NCT06169475Completed
- Start
- Nov 2020
- Primary completion
- Nov 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, single-blind trial of dexmedetomidine and esmolol in septic shock (3 arms). Primary endpoint: The cerebral hemodynamic change caused by the anti-stress therapy at 24 hours. Started Nov 2020; status: completed.
02
Drugs
dexmedetomidineesmolol
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT06169475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06169475.